Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.51M Buy
+37,300
New +$2.49M ﹤0.01% 1781
2026
Q1
Sell
-87,100
Closed -$5.78M 3769
2025
Q4
$5.78M Buy
87,100
+67,600
+347% +$4.37M 0.01% 1065
2025
Q3
$1.31M Sell
19,500
-64,200
-77% -$5.08M ﹤0.01% 2083
2025
Q2
$7.31M Buy
83,700
+57,400
+218% +$4.5M 0.02% 851
2025
Q1
$1.8M Buy
26,300
+21,700
+472% +$1.77M 0.01% 1427
2024
Q4
$358K Buy
+4,600
New +$341K ﹤0.01% 2469
2024
Q3
Sell
-2,400
Closed -$272K 2800
2024
Q2
$272K Sell
2,400
-4,800
-67% -$607K ﹤0.01% 2043
2024
Q1
$999K Sell
7,200
-6,700
-48% -$842K 0.01% 1332
2023
Q4
$1.72M Sell
13,900
-4,200
-23% -$429K 0.01% 1171
2023
Q3
$1.69M Buy
18,100
+13,700
+311% +$1.54M 0.02% 1018
2023
Q2
$565K Buy
+4,400
New +$532K 0.01% 1644
2023
Q1
Sell
-9,800
Closed -$1.11M 2538
2022
Q4
$1.11M Buy
+9,800
New +$1.08M 0.02% 1033
2022
Q3
Sell
-6,100
Closed -$453K 2401
2022
Q2
$453K Buy
+6,100
New +$557K 0.01% 1326

Other funds holding DXCM

Paul Tudor Jones's DXCM Position: Q1 2026 in Review

Paul Tudor Jones sold out of DexCom (DXCM) in Q1 2026, closing a stake of 24,004 shares — an estimated $1.67M sold.

Paul Tudor Jones first reported a position in DXCM in Q4 2013 and held it in 22 quarters. The position peaked at $4.81M in Q4 2023. 960 funds tracked by Wall St. Rank hold DXCM as of Q1 2026.

  • Paul Tudor Jones reported no remaining DexCom position as of Q1 2026 after selling out during the quarter.
  • Paul Tudor Jones sold 24,004 DexCom shares in Q1 2026, an estimated $1.67M.
  • Paul Tudor Jones first reported a position in DexCom in Q4 2013 and held it in 22 quarters.
  • Paul Tudor Jones's DexCom position peaked at $4.81M in Q4 2023.
  • 960 funds tracked by Wall St. Rank held DexCom as of Q1 2026.

Based on Tudor Investment Corp's 13F filing for Q1 2026, filed 15 May 2026.